Delamanid and pretomanid

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Pages2550-2558
Number of pages9
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
DOIs
StatePublished - Jan 1 2017

Fingerprint

Multidrug-Resistant Tuberculosis
Japan
Tuberculosis
Pharmaceutical Preparations
OPC-67683
2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine
4-nitroimidazole

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nuermberger, E., & Kendall, E. (2017). Delamanid and pretomanid. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2550-2558). CRC Press. https://doi.org/10.1201/9781315152110

Delamanid and pretomanid. / Nuermberger, Eric; Kendall, Emily.

Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. p. 2550-2558.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nuermberger, E & Kendall, E 2017, Delamanid and pretomanid. in Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, pp. 2550-2558. https://doi.org/10.1201/9781315152110
Nuermberger E, Kendall E. Delamanid and pretomanid. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press. 2017. p. 2550-2558 https://doi.org/10.1201/9781315152110
Nuermberger, Eric ; Kendall, Emily. / Delamanid and pretomanid. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. pp. 2550-2558
@inbook{67b2d051b0144c6995a7d1d58180f7fb,
title = "Delamanid and pretomanid",
abstract = "Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.",
author = "Eric Nuermberger and Emily Kendall",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9781315152110",
language = "English (US)",
isbn = "9781498747950",
pages = "2550--2558",
booktitle = "Kucers the Use of Antibiotics",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Delamanid and pretomanid

AU - Nuermberger, Eric

AU - Kendall, Emily

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.

AB - Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.

UR - http://www.scopus.com/inward/record.url?scp=85056690677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056690677&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

AN - SCOPUS:85056690677

SN - 9781498747950

SP - 2550

EP - 2558

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -